#bridgebio
Latest news and interesting information about bridgebio.
BioMarin Neutral Rating, $50 Target by HC Wainwright
H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.
BridgeBio SWOT: rare disease stock eyes profitability
SWOT analysis of BridgeBio Pharma: Attruby's strong launch, pipeline catalysts, and path to profitability. Rare disease stock outlook.
...

